Results 211 to 220 of about 276,777 (390)
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract
Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller +17 morewiley +1 more sourcePredicting 1‐year heart failure hospitalization and mortality post‐discharge from the intensive cardiac care unit
ESC Heart Failure, EarlyView.Abstract Aims
Despite the high risk of rehospitalization for heart failure (HF) and death among patients admitted to the intensive cardiac care unit (ICCU), no accurate prediction score for these outcomes exists. We aimed to develop a risk score to predict unplanned HF hospitalization and death 1‐year post‐discharge in an unselected cohort of patients ...Andreas Bugge Tinggaard, Solenn Toupin, Jean Guillaume Dillinger, Clément Delmas, Antonin Trimaille, Claire Bouleti, Guillaume Schurtz, Charles Fauvel, Jean Claude Dib, Stéphane Andrieu, François Roubille, Thomas Levasseur, Guillaume Bonnet, Marouane Boukhris, Thomas Bochaton, Vincent Roule, Laura Delsarte, Albert Boccara, Franck Albert, Franck Boccara, Etienne Puymirat, Henrik Wiggers, Alexandre Mebazaa, Alain Cohen‐Solal, Benjamin G. Chousterman, Patrick Henry, Théo Pezel, for the ADDICT‐ICCU Investigators, Victor Aboyans, Emeric Albert, Franck Albert, Sean Alvain, Nabil Amri, Stéphane Andrieu, Sabir Attou, Simon Auvray, Sonia Azzakani, Ruben Azencot, Marc Bedossa, Franck Boccara, Albert Boccara, Thomas Bochaton, Eric Bonnefoy‐Cudraz, Guillaume Bonnet, Nabil Bouali, Océane Bouchot, Claire Bouleti, Tanissia Boukertouta, Marouane Boukhris, Jean Baptiste Brette, Marjorie Canu, Aures Chaib, Clement Charbonnel, Anne Solene Chaussade, Alexandre Coppens, Yves Cottin, Arthur Darmon, Elena De Angelis, Clément Delmas, Laura Delsarte, Antoine Deney, Jean Claude Dib, Jean‐Guillaume Dillinger, Clemence Docq, Valentin Dupasquier, Meyer Elbaz, Antony El Hadad, Amine El Ouahidi, Nacim Ezzouhairi, Julien Fabre, Damien Fard, Charles Fauvel, Édouard Gerbaud, Martine Gilard, Marc Goralski, Nissim Grinberg, Alain Grentzinger, Marie Hauguel‐Moreau, Patrick Henry, Fabien Huet, Thomas Landemaine, Benoit Lattuca, Léo Lemarchand, Thomas Levasseur, Pascal Lim, Laura Maitre Ballesteros, Nicolas Mansencal, Benjamin Marie, David Martinez, Benoit Merat, Christophe Meune, Damien Millischer, Thomas Moine, Pascal Nhan, Nathalie Noirclerc, Patrick Ohlmann, Théo Pezel, Fabien Picard, Nicolas Piliero, Thibaut Pommier, Etienne Puymirat, Arthur Ramonatxo, Reza Rossanaly Vasram, François Roubille, Vincent Roule, Guillaume Schurtz, Mathilde Stevenard, David Sulman, Fédérico Swedsky, Victoria Tea, Eugénie Thevenet, Christophe Thuaire, Antonin Trimaille, Christophe Tron, Guillaume Viboud, Dominique Yomi, Cyril Zakine +116 morewiley +1 more sourceA phenomap of TTR amyloidosis to aid diagnostic screening
ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.Abstract
Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.Alexios S. Antonopoulos, Theodoros Tsampras, George Lazaros, Konstantinos Tsioufis, Charalambos Vlachopoulos +4 morewiley +1 more sourceFDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.Abstract Aims
Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.Sanjay Divakaran, Vinay Randhawa, Usman A. Tahir, Matthew Robertson, Anam A. Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W. Feinberg, Marcelo F. Di Carli, Neal K. Lakdawala +10 morewiley +1 more sourceMortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score
ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.Abstract Background and objectives
Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel +12 morewiley +1 more source